Japan's Takeda Pharmaceutical has reached an agreement to distribute Kaketsuken's influenza vaccine domestically in the 2015-2016 season as the government makes a major push to cover the elderly population. The company will also continue to distribute seasonal influenza vaccine Seiken manufactured by Denka Seiken. In 2014, Takeda received approval for a new drug application of a cell culture-based influenza vaccine for the prevention of pandemic influenza. It is also developing a cell culture-based seasonal influenza vaccine called TAK-850. Release | More from FierceVaccines